Next Generation Probiotics Market, by Bacterial Candidate (Akkermansia, Clostridium species, Bifidobacterium species, Lactobacillus species, and Others (Faecalibacterium, Christensenella,etc.)), by Application (Weight Management, Glucose Management, Inflammatory Bowel Diseases, and Others (Obesity, Metabolic Diseases, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023

Code : CMI5468

Pages :178

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Next Generation Probiotics Market- Drivers

Increasing product launches by key players in market are expected to drive market growth over the forecast period. For instance, in June 2021, FitBiomics, a sports biotechnology company, launched its first consumer product under Nella Brand, a next-generation probiotics supplement for gut health in active adults uniquely sourced from the microbiome of elite athletes.

Moreover, in September 2020, Lonza, a leading global provider of integrated healthcare solutions, announced the launch of its L. plantarum (TWK10) ingredient, which is originally isolated from fermented vegetables, specifically Taiwanese Kimchi. The unique patented TWK10 strain is the next generation of probiotics. It is also a novel probiotic designed to deliver sports nutrition benefits for both elite athletes and active consumers. The TWK10 brand is clinically shown to enhance endurance and improve body composition and energy levels.

Global Next Generation Probiotics Market: Restraint

Difficulties associated with the production of next-generation probiotics is expected to hinder the growth of the global next generation probiotics market. For instance, according to an article published by Network of Aquaculture Centres in Asia Pacific, an intergovernmental organization that promotes rural development through sustainable aquaculture and aquatic resources management, in 2021, NGP falls under the category of LBPs (live biotherapeutics) or drugs. Any probiotic strain that will be used as NGP is subject to the usual pharmaceutical clinical trials and research on its pharmacokinetics, pharmacodynamics, safety, and delivery routes. This process is stringent and poses significant hurdles on the pathway of NGP development and commercialization.